Cogent Biosciences (COGT) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic pipeline and clinical development

• Lead asset bezuclastinib is a selective KIT inhibitor in three pivotal trials for systemic mastocytosis and GIST, with all top-line results expected in 2025.

• FGFR2 inhibitor CGT4859 is in phase I for FGFR-mutant cancers, with two more INDs (CNS-penetrant ErbB2 and PI3K alpha inhibitors) planned by year-end.

• Pan-KRAS inhibitor in preclinical stage shows promising picomolar activity across KRAS mutants.

• Strong financial position with $345M cash as of Q3, supporting operations into 2026 post-trial readouts.

Clinical trial progress and timelines

• SUMMIT trial for non-advanced systemic mastocytosis fully enrolled ahead of schedule; top-line data expected July 2025.

• PEAK phase III study in imatinib-resistant GIST completed enrollment; results anticipated by end of 2025.

• APEX study for advanced systemic mastocytosis closed to screening, with top-line results in the second half of 2025.

Efficacy, safety, and market opportunity

• Bezuclastinib shows high symptomatic improvement (56% mean at 24 weeks, 76% of patients with ≥50% improvement) in SUMMIT, outperforming benchmarks.

• Safety profile is favorable, with main side effects being reversible lab changes and hair whitening, and no serious liver or CNS toxicity.

• Commercial opportunity for bezuclastinib exceeds $3B across indications, with limited competition in mastocytosis and strong positioning in second-line GIST.